Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paulette A Lyle

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Blood Pressure|April 25, 2007
Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?Björn Dahlöf, Richard B Devereux, Sverre E Kjeldsen, et al.
Clinical Therapeutics|December 13, 2006
A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertensionGilbert W Gleim, Joseph Rubino, Hongyan Zhang, et al.
Clinical Therapeutics|June 18, 2003
An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension StudyKrister Kristianson, Frej Fyhrquist, Richard B Devereux, et al.
Diabetes Care|March 1, 2006
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE studyHans Ibsen, Michael H Olsen, Kristian Wachtell, et al.
Hypertension (Dallas, Tex. : 1979)|February 9, 2008
Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension StudyIngrid Os, Veronica Franco, Sverre E Kjeldsen, et al.
Journal of the American Society of Nephrology : JASN|January 18, 2008
ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathyHans-Henrik Parving, Dick de Zeeuw, Mark E Cooper, et al.
Diabetes Care|December 12, 2007
Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL studyAndrew M Tershakovec, William F Keane, Zhongxin Zhang, et al.
The American Journal of Cardiology|August 28, 2007
Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study)Marianne L Smebye, Emil K Iversen, Aud Høieggen, et al.
The American Journal of Cardiology|November 29, 2005
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studiesAlbert A Carr, Peter R Kowey, Richard B Devereux, et al.
Expert Opinion on Emerging Drugs|November 3, 2005
Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockersSverre E Kjeldsen, Paulette A Lyle, Andrew M Tershakovec, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Blood Pressure|April 25, 2007
Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?Björn Dahlöf, Richard B Devereux, Sverre E Kjeldsen, et al.
Clinical Therapeutics|December 13, 2006
A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertensionGilbert W Gleim, Joseph Rubino, Hongyan Zhang, et al.
Clinical Therapeutics|June 18, 2003
An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension StudyKrister Kristianson, Frej Fyhrquist, Richard B Devereux, et al.
Diabetes Care|March 1, 2006
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE studyHans Ibsen, Michael H Olsen, Kristian Wachtell, et al.
Hypertension (Dallas, Tex. : 1979)|February 9, 2008
Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension StudyIngrid Os, Veronica Franco, Sverre E Kjeldsen, et al.
Journal of the American Society of Nephrology : JASN|January 18, 2008
ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathyHans-Henrik Parving, Dick de Zeeuw, Mark E Cooper, et al.
Diabetes Care|December 12, 2007
Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL studyAndrew M Tershakovec, William F Keane, Zhongxin Zhang, et al.
The American Journal of Cardiology|August 28, 2007
Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study)Marianne L Smebye, Emil K Iversen, Aud Høieggen, et al.
The American Journal of Cardiology|November 29, 2005
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studiesAlbert A Carr, Peter R Kowey, Richard B Devereux, et al.
Expert Opinion on Emerging Drugs|November 3, 2005
Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockersSverre E Kjeldsen, Paulette A Lyle, Andrew M Tershakovec, et al.
Pageof 3